“The GLP-compliant definitive repeat dose VNZ single agent studies were carried out for durations up to 28-days in mouse, 6 months in rat and 9 months in dog.”
No surrogate; vanzacaftor tested directly; deutivacaftor relied on bridged ivacaftor data
“The nonclinical program for NDA 218730 primarily focused on evaluation of the safety of the new molecular entity VNZ. The Applicant established a scientific bridge to leverage the nonclinical toxicity data from the IVA program (NDA 203188, Trade name: KALYDECO [tablet]) to characterize the safety profile of D-IVA.”